Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
7
×
fda
7
×
life sciences
national blog main
7
×
san francisco blog main
biotech
national top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
loxo oncology
blueprint medicines
deals
eli lilly
europe blog main
roche
black diamond therapeutics
cancer drugs
cancer immunotherapy
europe top stories
What
cancer
7
×
drug
fda
roundup
ahead
bio
biotech
black
cash
days
marketing
medicine
medicines
new
targets
abbvie’s
ambien
american
annual
appetite
approval
approved
asco
attendees
attention
biofourmis
blueprint
bread
bucks
butter
buyout
camp’s
candidate
celebrate
chance
chicago
city
clinic
clinical
combinations
Language
unset
Current search:
fda
×
" national blog main "
×
" clinical trials "
×
cancer
×
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More